Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-10-04

FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)

View source ↗

Summary

The FDA approved a supplemental application for Aimovig (erenumab-aooe) from Amgen to update the product’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AIMOVIG (ERENUMAB-AOOE)

Snippet

SUPPL AP for AIMOVIG (ERENUMAB-AOOE)